CytoSorbents' Q3 shows cash-flow neutrality, but German slump and thin cash balance persist

CytoSorbents said it covered its operating cash costs in the third quarter, a milestone for a company that has been loss-making, though the claim comes with a caveat: the figure leaves out restructuring payments. Results were published on 12 November.

Sales for the three months came to $9.7M, up 3% on the same period a year earlier, with gross margin at 75%. The operating loss narrowed by 59% to $1.2M. Taken together, the numbers point to a business whose improvement stems more from cost control and margin than from top-line momentum.

The company closed the quarter with roughly $5.7M in cash. Against quarterly revenue of $9.7M, that is a modest cushion, and the update as summarised does not set out how the company plans to fund operations beyond the quarter.

CytoSorbents framed its strategy around four value drivers. Two were highlighted: pursuing FDA marketing authorization for DrugSorb-ATR in the US, and rebuilding sales in Germany, where revenue declined 20%. The information available does not say which regulatory pathway the company is following for DrugSorb-ATR, nor does it give a timeline for any FDA milestone.

By way of context, US medical devices typically reach the market through FDA clearance, De Novo classification or premarket approval, depending on risk and on whether a suitable predicate device exists. Which of these applies to DrugSorb-ATR is not stated in the material reviewed.